title: Effects of prenatal exposure to neuroleptic drugs on children's growth.
abstract: The effect of prenatal exposure to neuroleptic drugs on height and weight from birth to 7 years was examined in children of psychiatrically normal parents and of parents with a history of psychiatric treatment, using data from the Collaborative Perinatal Project of the National Institute of Neurological Diseases, Communicative Disorders, and Stroke. Analysis of covariance was used to control for potential confounding factors. We found that prenatal exposure to dopamine receptor-blocking neuroleptic drugs was associated with increased height in one or more of our groups at 4 months, 1 year, and 7 years and less consistently with increased weight. Seven-year-old children who had been exposed to these drugs for more than 2 months during gestation were approximately 3 cm taller than unexposed controls (p less than 0.05). Prenatal exposure to dopamine-depleting agents was associated with decreased height at 4 months but not later. Possible mechanisms for these effects, including a permanent decrease in the number of brain dopamine receptors and effects on various hormones, are discussed.
authors.affiliation: Department of Psychiatry, New York University School of Medicine, NY 10016.
authors.forename: J E
authors.initials: JE
authors.lastname: Platt
authors.forename: A J
authors.initials: AJ
authors.lastname: Friedhoff
authors.forename: S H
authors.initials: SH
authors.lastname: Broman
authors.forename: R N
authors.initials: RN
authors.lastname: Bond
authors.forename: E
authors.initials: E
authors.lastname: Laska
authors.forename: S P
authors.initials: SP
authors.lastname: Lin
mesh_terms: D014150:Antipsychotic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001724:Birth Weight / Q000187:drug effects*; D001827:Body Height / Q000187:drug effects*; D001835:Body Weight / Q000187:drug effects*; D005260:Female; D006128:Growth / Q000187:drug effects*; D006801:Humans; D007231:Infant, Newborn; D008137:Longitudinal Studies; D008431:Maternal-Fetal Exchange; D001523:Mental Disorders / Q000188:drug therapy*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D011346:Prochlorperazine / Q000494:pharmacology / Q000627:therapeutic use; D012016:Reference Values
chemical_list: D014150:Antipsychotic Agents; D011346:Prochlorperazine